Description: Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Home Page: www.mersana.com
MRSN Technical Analysis
840 Memorial Drive
Cambridge,
MA
02139
United States
Phone:
617 498 0020
Officers
| Name | Title |
|---|---|
| Ms. Anna Protopapas M.B.A. | Pres, CEO & Director |
| Mr. Brian C. DeSchuytner | Sr. VP & CFO |
| Dr. Timothy B. Lowinger Ph.D. | Chief Science & Technology Officer |
| Ms. Alejandra Veronica Carvajal J.D. | SVP, Sec. & Chief Legal Officer |
| Dr. Tushar Misra Ph.D. | SVP & Chief Manufacturing Officer |
| Mr. Mikhail Papisov Ph.D. | Co-Founder |
| Mr. Ashish Mandelia | VP, Controller & Principal Accounting Officer |
| Mr. Jason Fredette | Sr. VP of Investor Relations & Corp. Communications |
| Ms. Carla Poulson | Chief People Officer |
| Mr. Chuck Miller | Sr. VP of Regulatory Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.1434 |
| Price-to-Sales TTM: | 57.8327 |
| IPO Date: | 2017-06-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 169 |